EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia






Journal of the American College of Cardiology 5(6): 1407-1413

Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia

The effects of the antiarrhythmic agent propafenone were evaluated in 25 patients with recurrent symptomatic ventricular tachycardia. Oral propafenone was given to a maximal dose of 300 mg every 8 h. Of the 25 patients 10 developed side effects or had inadequate suppression of spontaneous ventricular arrhythmias during propafenone therapy. Electrophysiologic studies were performed before and during drug therapy on the 15 patients who had a satisfactory clinical response. Propafenone increased the PR interval from 168 .+-. 46 to 188 .+-. 25 ms (P < 0.007), the HV interval from 47 .+-. 10 to 65 .+-. 13 ms (P < 0.005), the shortest atrial pacing cycle length to maintain 1:1 atrioventricular (AV) nodal conduction from 385 .+-. 44 to 436 .+-. 42 ms (P < 0.005), the ventricular effective refractory period from 231 .+-. 17 to 255 .+-. 19 ms (P < 0.001) and the ventricular functional refractory period from 260 .+-. 15 to 278 .+-. 17 ms (P < 0.002). Before propafenone therapy, all 15 patiets had ventricular tachycardia induced by programed ventricular stimulation. During propafenone treatment, 12 patients still had ventricular tachycardia induced and the tachycardia cycle length significantly increased from 236 .+-. 44 to 374 .+-. 103 ms (P < 0.001). Ten patients were considered to have satisfactory electrophysiologic response to propafenone on the basis of either the inability to intitate ventricular tachycardia or a marked increase in ventricular tachycardia cycle length associated with lack of symptoms during the induced tachycardia. These patients were discharged receiving propafenone. During a mean follow-up period of 11 mo., 8 of the 10 patients remained free of ventricular tachycardia, while 2 had a recurrence. Propafenone significantly depresses AV nodal and His-Purkinje conduction, lengthens ventricular refractoriness and markedly increases ventricular tachycardia cycle length. Induction of ventricular tachycardia at electrophysiologic study does not always augur recurrence of spontaneous tachycardia.

Accession: 005349277

PMID: 3889099

DOI: 10.1016/s0735-1097(85)80357-0

Download PDF Full Text: Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia



Related references

Electrophysiologic effects and clinical efficacy of propafenone in pediatric patients with paroxysmal supraventricular reentrant tachycardia. Giornale Italiano di Cardiologia 16(4): 336-343, 1986

Electrophysiologic effects and clinical efficacy of propafenone p in children with recurrent paroxysmal supraventricular tachycardia pst. European Heart Journal 8(ABSTR SUPPL 2): 97, 1987

Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. American Journal of Cardiology 52(10): 1208-1213, 1983

Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia. Journal of the American College of Cardiology 3(5): 1291-1297, 1984

Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation. American Journal of Cardiology 51(5): 759-764, 1983

Electrophysiologic effects and clinical efficacy of flecainide in patients with ventricular tachycardia. Journal of the American College of Cardiology 9(2 SUPPL A): 71A, 1987

Electrophysiologic effects and clinical efficacy of mexiletine in patients with refractory ventricular tachycardia. Clinical Research 34(2): 314A, 1986

Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. American Heart Journal 123(1): 82-89, 1992

Electrophysiologic parameters to predict clinical recurrence of ventricular tachycardia in patients under electrophysiologic study-guided effective pharmacological therapy. Japanese Circulation Journal 63(9): 674-680, 1999

Electrophysiologic effects efficacy and safety of oral moricizine hydrochloride in sustained ventricular tachycardia. Clinical Pharmacology & Therapeutics 37(2): 186, 1985